{'fraction_non_alphanumeric': 0.03412073490813648, 'fraction_numerical': 0.02799650043744532, 'mean_word_length': 5.150537634408602, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The assessment of the effect of glucocorticosteroid and nonsteroidal anti-inflammatory preparations on the development of an erosive-ulcerative lesion of the gastrointestinal tract in patients with rheumatic diseases].

AIM
A comparative evaluation of the frequency and severity of upper gastrointestinal mucosal lesions in patients taking nonsteroid anti-inflammatory drugs (NSAID) and glucocorticosteroids (GCS).


MATERIALS AND METHODS
The trial entered 1086 rheumatic patients examined endoscopically. To compare the effects of their medicines, the patients were divided into 3 groups: 726 patients on NSAID alone (group 1); 238 patients on NSAID and GCS (group 2); 122 patients on GCS only (group 3).


RESULTS
Gastropathies were diagnosed in 38.2, 32.4, 12.5% of group 1, 2 and 3 patients, respectively (the difference is significant). More serious diseases prevailed in group 1: multiple erosions and gastroduodenal ulcers. Group 2 and 3 patients had erosions only.


CONCLUSION
GCS are safer for gastrointestinal mucosa than NSAID. Combination of NSAID with GCS does not increase the risk of gastropathy onset compared to NSAID alone.